Genomic Urine Testing Market: Growth Drivers and Market Evolution

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Genomic Urine Testing Market Expected To Reach Based On Its 2026 Value?

The genomic urine testing market size has shown rapid expansion in recent years. It is anticipated to increase from $1.01 billion in 2025 to $1.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.5%. This historical growth can be attributed to advancements in molecular diagnostics, the necessity for non-invasive testing, foundational biomarker research, the adoption of genomic assays by laboratories, and the expansion of oncology diagnostics.

The genomic urine testing market is anticipated to experience substantial growth over the next few years. It is forecast to achieve a valuation of $1.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.2%. This expansion during the forecast period is propelled by its integration into routine health screenings, its extended use for infectious disease detection, advancements in technological sensitivity, the increasing need for personalized monitoring, and successful clinical validation studies. Notable trends during this period include the rising acceptance of non-invasive diagnostic testing, an increased application of genomic biomarkers in disease detection, the growing requirement for early cancer screening tools, the broadening of personalized diagnostic methods, and intensified research efforts in urinary genomic profiling.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

What Primary Drivers Are Shaping The Genomic Urine Testing Market?

The rising prevalence of chronic kidney disease is anticipated to boost the expansion of the genomic urine testing market in the future. Chronic kidney disease (CKD) describes a state where kidney damage impairs their ability to filter blood, resulting in an accumulation of waste products and excess fluids within the body. This increase in the burden of CKD stems from the growing incidence of diabetes, given that elevated blood sugar levels harm renal blood vessels, compromising their waste-filtering capacity. Genomic urine testing contributes to CKD management by enabling the early identification of genetic indicators, facilitating prompt interventions and tailored treatment strategies. It improves patient results through more precise monitoring and by slowing the advancement of the disease. For instance, as reported in November 2025 by The American Journal of Managed Care, a US-based peer-reviewed medical publication, there were 788 million adults aged 20 and above living with CKD in 2023. Consequently, the escalating burden of chronic kidney disease is a primary catalyst for the growth of the genomic urine testing market.

What Are The Main Segments Within The Genomic Urine Testing Market Segment Structure?

The genomic urine testing market covered in this report is segmented –

1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing

2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies

3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:

1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis

2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection

3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis

4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing

What Trends Are Affecting The Growth Of The Genomic Urine Testing Market?

Major companies in the genomic urine testing market are focused on developing innovative solutions, such as next-generation sequencing, to enhance the accuracy, sensitivity, and early detection capabilities of non-invasive diagnostic tests for various diseases. Next-generation sequencing (NGS) is an advanced DNA sequencing technology that enables rapid, accurate, and large-scale analysis of genetic material by simultaneously sequencing millions of deoxyribonucleic acid (DNA) fragments. For instance, in May 2023, Convergent Genomics Inc., a US-based biotechnology company, launched the genomic urine test UroAmp. This test utilizes next-generation deoxyribonucleic acid (DNA) sequencing to analyze mutations in 60 genes associated with bladder cancer, allowing for early detection up to 12 years before clinical symptoms manifest. It provides detailed genetic insights to guide diagnosis, treatment decisions, and recurrence monitoring, offering higher accuracy than traditional methods like cytology and cystoscopy.

Who Are The Companies Participating In The Genomic Urine Testing Market?

Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

Get The Full Genomic Urine Testing Market Report:

https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

Where Is The Genomic Urine Testing Market Primarily Concentrated By Region?

North America was the largest region in the genomic urine testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Genomic Urine Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

Browse Through More Reports Similar to the Global Genomic Urine Testing Market 2026, By The Business Research Company

Genetic Testing Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/genetic-testing-services-global-market-report

Genetic Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Dna Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/dna-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795